See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. After it paid $430 million to settle a 2004 lawsuit over illegal ...

Here's a depressing exchange in the litigation on Pfizer's anti-seizure med, Neurontin. It's between the doctor of Susan Bulger, who killed herself after taking the pill. Her family claims Pfizer knew ...

The mad rush to rid this country of demonic prescription analgesic drugs (mainly Vicodin and Percocet) has put pain patients and their doctors in an unprecedented dilemma. What can they do for pain ...

A division of Pfizer Inc., the world's largest drugmaker, has agreed to plead guilty to two felonies and pay $430 million in penalties to settle charges that it fraudulently promoted the drug ...

Pfizer (PFE)'s marketing team created a PowerPoint slide which depicted its anti-seizure drug Neurontin as a witch's brew (pictured) and its marketing unit as a magic cauldron -- an apparent ...

Wanna hear something sickening? Neurontin, a drug developed for epilepsy and used off-label for neuropathic pain, had its sales grow 250% between 2004 and 2019. Why? We don't have 250% more epileptics ...

Drug companies spend billons of dollars each year trying to persuade doctors to prescribe their drugs. There are strict rules about what form that promotion can take. The rules are meant to ensure ...

June 2 (Reuters) - Pfizer Inc has agreed to pay $325 million to resolve claims it defrauded insurers and other healthcare benefit providers by marketing Neurontin for unapproved uses, its second ...

300mg once on day 1, twice daily on day 2, and 3 times daily on day 3; may titrate up to usual max 1.8g/day in 3 divided doses (doses up to 3.6g/day have been used without added benefit). Renal ...

NEW YORK (Reuters Health) - A study of the safety and effectiveness of an anti-epilepsy drug mislead doctors and patients about the point of the research, suggests a new report. Investigators writing ...

(Reuters) - Pfizer Inc has agreed to pay $325 million to resolve claims it defrauded insurers and other healthcare benefit providers by marketing Neurontin for unapproved uses, its second settlement ...